Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...
Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...
Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...
A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...
Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback